JP2019516392A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516392A5
JP2019516392A5 JP2018567013A JP2018567013A JP2019516392A5 JP 2019516392 A5 JP2019516392 A5 JP 2019516392A5 JP 2018567013 A JP2018567013 A JP 2018567013A JP 2018567013 A JP2018567013 A JP 2018567013A JP 2019516392 A5 JP2019516392 A5 JP 2019516392A5
Authority
JP
Japan
Prior art keywords
seq
constant domain
ilt7
item
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018567013A
Other languages
English (en)
Japanese (ja)
Other versions
JP6979976B2 (ja
JP2019516392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021616 external-priority patent/WO2017156298A1/en
Publication of JP2019516392A publication Critical patent/JP2019516392A/ja
Publication of JP2019516392A5 publication Critical patent/JP2019516392A5/ja
Priority to JP2021186637A priority Critical patent/JP7354212B2/ja
Application granted granted Critical
Publication of JP6979976B2 publication Critical patent/JP6979976B2/ja
Priority to JP2023151943A priority patent/JP7700190B2/ja
Priority to JP2025101902A priority patent/JP2025134836A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018567013A 2016-03-10 2017-03-09 Ilt7結合分子及びその使用方法 Active JP6979976B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021186637A JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306125P 2016-03-10 2016-03-10
US62/306,125 2016-03-10
PCT/US2017/021616 WO2017156298A1 (en) 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021186637A Division JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019516392A JP2019516392A (ja) 2019-06-20
JP2019516392A5 true JP2019516392A5 (enExample) 2020-04-16
JP6979976B2 JP6979976B2 (ja) 2021-12-15

Family

ID=59790876

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018567013A Active JP6979976B2 (ja) 2016-03-10 2017-03-09 Ilt7結合分子及びその使用方法
JP2021186637A Active JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A Active JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A Pending JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021186637A Active JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A Active JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A Pending JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Country Status (16)

Country Link
US (3) US11072652B2 (enExample)
EP (1) EP3426298A4 (enExample)
JP (4) JP6979976B2 (enExample)
KR (5) KR20250051802A (enExample)
CN (2) CN109414499B (enExample)
AR (2) AR109450A1 (enExample)
AU (2) AU2017231833B2 (enExample)
CA (1) CA3017197A1 (enExample)
IL (2) IL261653B2 (enExample)
MX (2) MX2018010771A (enExample)
RU (1) RU2756109C2 (enExample)
SG (2) SG11201807523PA (enExample)
TW (1) TWI755380B (enExample)
UA (1) UA127731C2 (enExample)
WO (1) WO2017156298A1 (enExample)
ZA (1) ZA201806597B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ,インコーポレーテッド Ilt7結合分子及びその使用方法
US11787858B2 (en) * 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof
US11732041B2 (en) * 2019-04-19 2023-08-22 Allogene Therapeutics, Inc. Antibodies against 4G7-derived chimeric antigen receptors
IL293572A (en) * 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins
US20230055143A1 (en) * 2019-12-20 2023-02-23 Medimmune, Llc Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
MX2023013015A (es) 2021-05-04 2023-11-15 Viela Bio Inc Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).
WO2024026388A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
JP2025540348A (ja) 2022-12-12 2025-12-11 ビエラ バイオ インコーポレイテッド 筋炎の処置及び予防のための、抗ilt7結合剤
EP4680344A1 (en) * 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
TW202607041A (zh) * 2024-06-27 2026-02-16 大陸商無錫徠特康生物科技有限公司 靶向ilt7和cd89的髓細胞銜接子抗體及其用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096948A (en) 1935-12-20 1937-10-26 Anchor Steel & Conveyor Co Conveyer system
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440354A1 (de) 1994-11-11 1996-05-15 Hoechst Schering Agrevo Gmbh Kombinationen aus Phenylsulfonylharnstoff-Herbiziden und Safenern
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US6897067B2 (en) 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2470239C (en) 2002-03-20 2020-06-16 Catalina Marketing International, Inc. Targeted incentives based upon predicted behavior
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
US20070025992A1 (en) 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
US9208495B2 (en) 2003-10-06 2015-12-08 Yellowpages.Com Llc Methods and apparatuses for advertisement presentation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1851248B1 (en) * 2005-02-10 2016-08-10 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
SI1964852T1 (sl) 2005-12-20 2013-09-30 Sbi Biotech Co. Ltd. Proti-ilt7 protitelo
AU2007234733A1 (en) * 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US7781306B2 (en) 2007-06-20 2010-08-24 Semiconductor Energy Laboratory Co., Ltd. Semiconductor substrate and method for manufacturing the same
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2010065536A2 (en) 2008-12-01 2010-06-10 The Board Of Regents Of The University Of Texas System Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
WO2012149228A1 (en) 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
SG10201900183VA (en) 2011-04-28 2019-05-30 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
US8605807B1 (en) 2012-05-22 2013-12-10 Nigel Iain Stuart Macrae Communicating distinct data over a single frequency using multiple linear polarized signals
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US9114438B2 (en) 2013-05-21 2015-08-25 Applied Materials, Inc. Copper residue chamber clean
WO2016033547A1 (en) 2014-08-29 2016-03-03 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and oprl
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ,インコーポレーテッド Ilt7結合分子及びその使用方法
IL293572A (en) 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins
MX2023013015A (es) 2021-05-04 2023-11-15 Viela Bio Inc Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).

Similar Documents

Publication Publication Date Title
CN112135626A (zh) 抗tigit抗体及其用途
CN110536903A (zh) 抗ox40抗体及其用途
JP2022533538A5 (enExample)
WO2016000619A1 (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
JP2020508655A5 (enExample)
JP2014509861A5 (enExample)
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
CN113874400A (zh) 抗Vβ17/抗CD123双特异性抗体
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2012526558A5 (enExample)
RU2018135550A (ru) Связывающие ilt7 молекулы и способы их применения
JP2023519962A5 (enExample)
JP2024540148A5 (enExample)
CN109721656B (zh) 靶向rankl的治疗性抗体
RU2019135404A (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
JP2024516098A5 (enExample)
JP2025508835A5 (enExample)
JP2019528046A5 (enExample)
RU2019103991A (ru) Анти-il-22r-антитела
CN121851171A (zh) St2抗原结合蛋白
JP2023532248A5 (enExample)
JP2024523514A5 (enExample)
RU2020128108A (ru) Антитело против cd25 для опухоль-специфической клеточной деплеции
JP2021513357A5 (enExample)